SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Accelerate Diagnostics, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97’

On:  Thursday, 3/28/24, at 6:12pm ET   ·   As of:  3/29/24   ·   For:  12/31/23   ·   Accession #:  1628280-24-13670   ·   File #:  1-31822

Previous ‘10-K’:  ‘10-K’ on 3/31/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   30 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/29/24  Accelerate Diagnostics, Inc.      10-K       12/31/23  125:16M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.24M 
 2: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     46K 
 3: EX-10.17    Material Contract                                   HTML     80K 
 4: EX-10.30    Material Contract                                   HTML     71K 
 5: EX-21       Subsidiaries List                                   HTML     36K 
 6: EX-23.1     Consent of Expert or Counsel                        HTML     37K 
10: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     53K 
                Awarded Compensation                                             
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     40K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     40K 
 9: EX-32       Certification -- §906 - SOA'02                      HTML     36K 
16: R1          Cover Page                                          HTML    103K 
17: R2          Audit Information                                   HTML     40K 
18: R3          Consolidated Balance Sheets                         HTML    159K 
19: R4          Consolidated Balance Sheets (Parenthetical)         HTML     55K 
20: R5          Consolidated Statements of Operations and           HTML    141K 
                Comprehensive Loss                                               
21: R6          Consolidated Statements of Stockholders? Deficit    HTML    173K 
22: R7          Consolidated Statement of Cash Flows                HTML    192K 
23: R8          Organization and Nature of Business; Basis of       HTML     56K 
                Presentation; Principles of Consolidation                        
24: R9          Summary of Significant Accounting Policies          HTML    109K 
25: R10         Concentration of Credit Risk                        HTML     39K 
26: R11         Fair Value of Financial Instruments                 HTML     83K 
27: R12         Investments                                         HTML     56K 
28: R13         Inventory                                           HTML     43K 
29: R14         Property and Equipment                              HTML     53K 
30: R15         Deferred Revenue and Remaining Performance          HTML     57K 
                Obligations                                                      
31: R16         Leases                                              HTML    126K 
32: R17         Convertible Notes                                   HTML    115K 
33: R18         Related Party Transactions                          HTML     71K 
34: R19         Loss Per Share                                      HTML     47K 
35: R20         Equity-Based Compensation                           HTML    102K 
36: R21         Income Taxes                                        HTML    125K 
37: R22         Commitments and Contingencies                       HTML     38K 
38: R23         Geographic and Revenue Disaggregation               HTML     67K 
39: R24         Stockholders? Deficit                               HTML     46K 
40: R25         Subsequent Events                                   HTML     43K 
41: R26         Pay vs Performance Disclosure                       HTML     47K 
42: R27         Insider Trading Arrangements                        HTML     41K 
43: R28         Summary of Significant Accounting Policies          HTML    157K 
                (Policies)                                                       
44: R29         Summary of Significant Accounting Policies          HTML     55K 
                (Tables)                                                         
45: R30         Fair Value of Financial Instruments (Tables)        HTML     77K 
46: R31         Investments (Tables)                                HTML     53K 
47: R32         Inventory (Tables)                                  HTML     43K 
48: R33         Property and Equipment (Tables)                     HTML     55K 
49: R34         Deferred Revenue and Remaining Performance          HTML     51K 
                Obligations (Tables)                                             
50: R35         Leases (Tables)                                     HTML     81K 
51: R36         Convertible Notes (Tables)                          HTML    112K 
52: R37         Related Party Transactions (Tables)                 HTML     67K 
53: R38         Loss Per Share (Tables)                             HTML     44K 
54: R39         Equity-Based Compensation (Tables)                  HTML    105K 
55: R40         Income Taxes (Tables)                               HTML    120K 
56: R41         Geographic and Revenue Disaggregation (Tables)      HTML     67K 
57: R42         Organization and Nature of Business; Basis of       HTML    188K 
                Presentation; Principles of Consolidation                        
                (Details)                                                        
58: R43         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     43K 
                Schedule of Allowance for Credit Losses (Details)                
59: R44         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     70K 
                Narrative (Details)                                              
60: R45         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     42K 
                Schedule of Product Warranty Reserve Activity                    
                (Details)                                                        
61: R46         Concentration of Credit Risk (Details)              HTML     51K 
62: R47         FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of   HTML     94K 
                Financial Instruments Measured at Fair Value on a                
                Recurring Basis (Details)                                        
63: R48         FAIR VALUE OF FINANCIAL INSTRUMENTS - Narrative     HTML     86K 
                (Details)                                                        
64: R49         INVESTMENTS - Schedule of Debt Securities           HTML     77K 
                Classified as Available-for-Sale Investments                     
                (Details)                                                        
65: R50         INVESTMENTS - Narrative (Details)                   HTML     54K 
66: R51         INVESTMENTS - Schedule of Unrealized Losses or      HTML     37K 
                Gains on Equity Securities (Details)                             
67: R52         INVENTORY - Schedule of Inventories (Details)       HTML     44K 
68: R53         INVENTORY - Narrative (Details)                     HTML     37K 
69: R54         PROPERTY AND EQUIPMENT - Schedule of Property and   HTML     54K 
                Equipment, Net (Details)                                         
70: R55         PROPERTY AND EQUIPMENT - Narrative (Details)        HTML     37K 
71: R56         PROPERTY AND EQUIPMENT - Schedule of Instruments    HTML     43K 
                at Cost and Accumulated Depreciation, Lessor                     
                (Details)                                                        
72: R57         DEFERRED REVENUE AND REMAINING PERFORMANCE          HTML     46K 
                OBLIGATIONS - Schedule of Changes in Deferred                    
                Revenue (Details)                                                
73: R58         DEFERRED REVENUE AND REMAINING PERFORMANCE          HTML     48K 
                OBLIGATIONS - Narrative (Details)                                
74: R59         DEFERRED REVENUE AND REMAINING PERFORMANCE          HTML     46K 
                OBLIGATIONS - Schedule of Activity Related to BD                 
                Commercial Agreement (Details)                                   
75: R60         LEASES - Schedule of Supplemental Information       HTML     63K 
                Related to Leases and Lease Cost (Details)                       
76: R61         LEASES - Schedule of Maturities of Operating and    HTML     74K 
                Finance Lease Liabilities (Details)                              
77: R62         LEASES - Schedule of Maturities of Lease            HTML     57K 
                Receivables Under Sales-Type Leases (Details)                    
78: R63         CONVERTIBLE NOTES - Schedule of Long-Term Debt      HTML     53K 
                (Details)                                                        
79: R64         CONVERTIBLE NOTES - Schedule of Interest Expense    HTML     52K 
                (Details)                                                        
80: R65         CONVERTIBLE NOTES - Schedule of Gain (Loss) on      HTML     47K 
                Extinguishment (Details)                                         
81: R66         CONVERTIBLE NOTES - Schedule of Convertible Notes   HTML     65K 
                (Details)                                                        
82: R67         CONVERTIBLE NOTES - 2.50% Notes (Narrative)         HTML    165K 
                (Details)                                                        
83: R68         CONVERTIBLE NOTES - Restructuring Support           HTML     99K 
                Agreement and June 2023 Exchange Transactions                    
                (Narrative) (Details)                                            
84: R69         CONVERTIBLE NOTES - 5.00% Notes (Narrative)         HTML    137K 
                (Details)                                                        
85: R70         CONVERTIBLE NOTES - Schedule of Derivative          HTML     54K 
                Financial Instrument Activity (Details)                          
86: R71         CONVERTIBLE NOTES - Schedule of Significant         HTML     58K 
                Assumptions and Inputs Used to Estimate the Fair                 
                Value of Convertible Notes (Details)                             
87: R72         CONVERTIBLE NOTES - Fair Value of Conversion        HTML     50K 
                Option (Narrative) (Details)                                     
88: R73         CONVERTIBLE NOTES - Schedule of Significant         HTML     60K 
                Assumptions and Inputs Used to Estimate the Fair                 
                Value of Conversion Option (Details)                             
89: R74         RELATED PARTY TRANSACTIONS - March 2022 Securities  HTML     62K 
                Purchase Agreement (Narrative) (Details)                         
90: R75         RELATED PARTY TRANSACTIONS - August 2022 Exchange   HTML     95K 
                Agreement (Narrative) (Details)                                  
91: R76         RELATED PARTY TRANSACTIONS - Schedule of Carrying   HTML     57K 
                Value of the Secured Notes (Details)                             
92: R77         RELATED PARTY TRANSACTIONS - Warrant (Narrative)    HTML     49K 
                (Details)                                                        
93: R78         RELATED PARTY TRANSACTIONS - Conversion of Series   HTML     60K 
                A Preferred Stock to Common Stock (Narrative)                    
                (Details)                                                        
94: R79         RELATED PARTY TRANSACTIONS - Secured Note           HTML     64K 
                Amendment and Exchange (Narrative) (Details)                     
95: R80         RELATED PARTY TRANSACTIONS - Schuler Purchase       HTML     96K 
                Obligation (Narrative) (Details)                                 
96: R81         RELATED PARTY TRANSACTIONS - Schedule of            HTML     55K 
                Significant Assumptions and Inputs Used to                       
                Estimate the Fair Value of the Schuler Purchase                  
                Obligation (Details)                                             
97: R82         LOSS PER SHARE - Schedule of Potentially Issuable   HTML     46K 
                Common Shares Excluded from Computation of Diluted               
                Net Loss Per Share (Details)                                     
98: R83         LOSS PER SHARE - Narrative (Details)                HTML     81K 
99: R84         EQUITY-BASED COMPENSATION - 2022 Omnibus Equity     HTML     67K 
                Incentive Plan (Narrative) (Details)                             
100: R85         EQUITY-BASED COMPENSATION - Schedule of Stock       HTML     75K  
                Option Activity (Details)                                        
101: R86         EQUITY-BASED COMPENSATION - Schedule of Estimated   HTML     49K  
                Fair Value of Options Awarded (Details)                          
102: R87         EQUITY-BASED COMPENSATION - Schedule of Options     HTML     63K  
                Outstanding and Options Exercisable (Details)                    
103: R88         EQUITY-BASED COMPENSATION - Schedule of RSU         HTML     65K  
                Activity (Details)                                               
104: R89         EQUITY-BASED COMPENSATION - Schedule of Weighted    HTML     47K  
                Average Fair Value of RSUs Awarded (Details)                     
105: R90         EQUITY-BASED COMPENSATION - Schedule of Expense     HTML     62K  
                and Tax Benefit Related to Share-Based                           
                Compensation (Details)                                           
106: R91         EQUITY-BASED COMPENSATION - Narrative (Details)     HTML     82K  
107: R92         INCOME TAXES - Schedule of Components of Pretax     HTML     45K  
                Loss from Operations (Details)                                   
108: R93         INCOME TAXES - Schedule of Components of            HTML     63K  
                (Provision) Benefit for Income Taxes (Details)                   
109: R94         INCOME TAXES - Schedule of Deferred Income Taxes    HTML     75K  
                Components (Details)                                             
110: R95         INCOME TAXES - Narrative (Details)                  HTML    161K  
111: R96         INCOME TAXES - Schedule of Effective Tax Rate       HTML     66K  
                (Details)                                                        
112: R97         INCOME TAXES - Schedule of Uncertain Tax Positions  HTML     49K  
                (Details)                                                        
113: R98         Commitments and Contingencies (Details)             HTML     37K  
114: R99         GEOGRAPHIC AND REVENUE DISAGGREGATION - Narrative   HTML     53K  
                (Details)                                                        
115: R100        GEOGRAPHIC AND REVENUE DISAGGREGATION - Schedule    HTML     43K  
                of Long-lived Assets (Details)                                   
116: R101        GEOGRAPHIC AND REVENUE DISAGGREGATION - Schedule    HTML     56K  
                of Disaggregation of Revenue (Details)                           
117: R102        STOCKHOLDERS? DEFICIT - At-The-Market Equity Sales  HTML     50K  
                Agreement (Narrative) (Details)                                  
118: R103        STOCKHOLDERS? DEFICIT - August 2022 Public          HTML     50K  
                Offering (Narrative) (Details)                                   
119: R104        STOCKHOLDERS? DEFICIT - Treasury Stock (Narrative)  HTML     54K  
                (Details)                                                        
120: R105        SUBSEQUENT EVENTS - January 2024 Unit Offering      HTML     78K  
                (Narrative) (Details)                                            
122: XML         IDEA XML File -- Filing Summary                      XML    231K  
125: XML         XBRL Instance -- axdx-20231231_htm                   XML   2.60M  
121: EXCEL       IDEA Workbook of Financial Report Info              XLSX    268K  
12: EX-101.CAL  XBRL Calculations -- axdx-20231231_cal               XML    304K 
13: EX-101.DEF  XBRL Definitions -- axdx-20231231_def                XML   1.55M 
14: EX-101.LAB  XBRL Labels -- axdx-20231231_lab                     XML   2.42M 
15: EX-101.PRE  XBRL Presentations -- axdx-20231231_pre              XML   2.14M 
11: EX-101.SCH  XBRL Schema -- axdx-20231231                         XSD    249K 
123: JSON        XBRL Instance as JSON Data -- MetaLinks              744±  1.16M  
124: ZIP         XBRL Zipped Folder -- 0001628280-24-013670-xbrl      Zip    705K  


‘EX-97’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  

EXHIBIT 97

ACCELERATE DIAGNOSTICS, INC.
Clawback Policy for the Recovery of Erroneously Awarded Compensation
In accordance with the applicable rules of The Nasdaq Stock Market (the “NASDAQ Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Board of Directors (the “Board”) of Accelerate Diagnostics, Inc. (“Accelerate”) has adopted this Policy (this “Policy”) effective as of December 1, 2023 to provide for the recovery of erroneously awarded Incentive-Based Compensation from Section 16 Officers.
All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section 2, below.
1.Applicability. This Policy applies to all Incentive-Based Compensation Received by a Section 16 Officer (each as defined below).
2.Definitions. For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.
Accounting Restatement” means an accounting restatement due to the material noncompliance of Accelerate with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a “Big R” restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a “little r” restatement). An out-of-period of adjustment – when the error is immaterial to the previously issued financial statements, and the correction of the error is also immaterial to the current period – does not trigger a compensation recovery under this Policy because it is not an “accounting restatement”.
Clawback Eligible Incentive Compensation” means all Incentive-Based Compensation Received by a Section 16 Officer (i) on or after October 2, 2023; (ii) after beginning service as a Section 16 Officer; (iii) who served as a Section 16 Officer at any time during the applicable performance period relating to any Incentive-Based Compensation (whether or not such Section 16 Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to Accelerate); (iv) while Accelerate has a class of securities listed on a national securities exchange or a national securities association; and (v) during the applicable Clawback Period (as defined below).
Clawback Period” means, with respect to any Accounting Restatement, the three completed fiscal years of Accelerate immediately preceding the Restatement Date (as defined below), and if Accelerate changes its fiscal year, any transition period of less than nine months within or immediately following those three completed fiscal years.
Erroneously Awarded Compensation” means, with respect to each Section 16 Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.
Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing Accelerate’s financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in Accelerate’s financial statements or included in a filing with the SEC.
Incentive-Based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
NASDAQ” means The Nasdaq Stock Market.
Received” means, with respect to any Incentive-Based Compensation, actual or deemed receipt. Incentive-Based Compensation shall be deemed received in Accelerate’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation to the Section 16 Officer occurs after the end of that period.
For purposes of illustration only, a performance-based stock unit award is made to an executive (i) with the number of units determined at the end of a three-year performance period ending on December 31, 2022 and (ii) subject to continued employment until December 31, 2024. While the executive would not have a non-forfeitable interest in the award until the end of 2024, if an Accounting Restatement was made in 2023 for any of the fiscal years within the three-year Clawback Period (fiscal years 2020, 2021 or



2022), this Policy would require a recalculation of the number of units that will ultimately vest at the end of 2024.

Restatement Date” means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of Accelerate authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that Accelerate is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs Accelerate to prepare an Accounting Restatement.
Section 16 Officer” means each individual who is currently or was previously designated as an “officer” of Accelerate as defined in Rule 16a-1(f) under the Exchange Act, including the president, principal financial officer, principal accounting officer, any vice-president of the issuer in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for Accelerate. For the avoidance of doubt, the identification of Section 16 Officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).
1.Recovery of Erroneously Awarded Compensation.
a.In the event of an Accounting Restatement, Accelerate will reasonably promptly recover the Erroneously Awarded Compensation Received in accordance with NASDAQ rules and Rule 10D-1 as follows:
a.After an Accounting Restatement, the Compensation and Nominating Committee (if composed entirely of independent directors, or in the absence of such a committee, a majority of independent directors serving on the Board) (the “Committee”) shall determine the amount of any Erroneously Awarded Compensation Received by each Section 16 Officer and shall promptly notify each Section 16 Officer with a written notice containing the amount of any Erroneously Awarded Compensation and a demand for repayment or return of such compensation, as applicable.
For Incentive-Based Compensation based on (or derived from) Accelerate’s stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement:
a.The amount to be repaid or returned shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on Accelerate’s stock price or total shareholder return upon which the Incentive-Based Compensation was Received; and
b.Accelerate shall maintain documentation of the determination of such reasonable estimate and provide the relevant documentation as required to NASDAQ.
a.The Committee shall have discretion to determine the appropriate means of recovering Erroneously Awarded Compensation based on the particular facts and circumstances.
Accelerate shall pursue the recovery of the compensation subject to this Policy reasonably promptly, using an appropriate balance of cost and speed in determining the appropriate means to seek recovery. Accelerate may establish a deferred payment plan that allows repayment by a Section 16 Officer as soon as possible without unreasonable economic hardship to the Section 16 Officer, depending on the particular facts and circumstances. A deferred repayment plan would generally not be a prohibited personal loan, but unpaid amounts would be subject to disclosure under Item 402 of Regulation S-K.
Notwithstanding the foregoing, except as set forth in Section 3(b) below, in no event may Accelerate accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of a Section 16 Officer’s obligations hereunder.
a.To the extent that the Section 16 Officer has already reimbursed Accelerate for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by Accelerate or applicable law, such reimbursed amount will to be credited to the amount of Erroneously Awarded Compensation that is subject to recovery under this Policy.
b.To the extent that a Section 16 Officer fails to repay all Erroneously Awarded Compensation to Accelerate when due, Accelerate shall take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Section 16 Officer. The applicable Section 16 Officer shall be required to reimburse Accelerate for any and all expenses reasonably incurred (including legal fees) by Accelerate in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.



a.Notwithstanding anything herein to the contrary, Accelerate shall not be required to take the actions contemplated by Section 3(a) above if the Committee determines that recovery would be impracticable and any of the following two conditions are met:
a.The Committee has determined that the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making this determination, Accelerate must make a reasonable attempt to recover the Erroneously Awarded Compensation, document such attempt(s), and provide such documentation to NASDAQ; or
b.Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of Accelerate, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.
1.Disclosure Requirements. Accelerate shall file all disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission (“SEC”) filings and rules.
2.Prohibition of Indemnification. Accelerate shall not insure or indemnify any Section 16 Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy; or (ii) any claims relating to Accelerate’s enforcement of its rights under this Policy.
3.No Exemption. Accelerate shall not enter into any agreement that exempts any Incentive-Based Compensation that is granted, paid or awarded to a Section 16 Officer from the application of this Policy or that waives Accelerate’s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date of this Policy).
Each Section 16 Officer shall sign a return a copy of the Attestation and Acknowledgement attached to this Policy as Exhibit A before any Incentive-Based Compensation is Received by such Section 16 Officer.
1.Administration and Interpretation. This Policy shall be administered by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy and for Accelerate’s compliance with NASDAQ Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule or interpretation of the SEC or NASDAQ promulgated or issued in connection therewith.
2.Amendment; Termination. The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section 7 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by Accelerate contemporaneously with such amendment or termination) cause Accelerate to violate any federal securities laws, SEC rule or NASDAQ rule.
3.Other Recovery Rights. This Policy shall be binding and enforceable against all Section 16 Officers and, to the extent required by applicable law or guidance from the SEC or NASDAQ, their beneficiaries, heirs, executors, administrators or other legal representatives. The Board intends that this Policy will be applied to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensation plan or any other agreement or arrangement with a Section 16 Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Section 16 Officer to abide by the terms of this Policy.
Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to Accelerate under applicable law, regulation or rule or pursuant to the terms of any policy of Accelerate or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement.
Secretary’s Certificate

This Accelerate Diagnostics, Inc. Clawback Policy for the Recovery of Erroneously Awarded Compensation was unanimously approved by the Board at its meeting on November 8, 2023.


/s/ Davide Patience
David Patience, Secretary






Exhibit A

ACCELERATE DIAGNOSTICS, INC.
Clawback Policy for the Recovery of Erroneously Awarded Compensation
Attestation and Acknowledgement
By my signature below, I acknowledge and agree that:
I have received and read the attached Clawback Policy for the Recovery of Erroneously Awarded Compensation (the “Policy”).
I hereby agree to abide by all of the terms of this Policy both during and after my employment with Accelerate, including, without limitation, by promptly repaying or returning any Erroneously Awarded Compensation to Accelerate as determined in accordance with the Policy.


Signature Date



Name





Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
12/31/24
Filed as of:3/29/24
Filed on:3/28/24
For Period end:12/31/23
12/1/23
11/8/23
10/2/23
12/31/2210-K,  SD
 List all Filings 


30 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/25/24  Accelerate Diagnostics, Inc.      8-K:1,3,9   1/19/24   12:507K                                   Toppan Merrill/FA
 1/18/24  Accelerate Diagnostics, Inc.      S-1/A                  5:1.4M                                   Toppan Merrill/FA
12/13/23  Accelerate Diagnostics, Inc.      8-K:1,7,8,912/11/23   14:3.6M                                   Toppan Merrill/FA
 7/13/23  Accelerate Diagnostics, Inc.      8-K:3,5,8,9 7/11/23   11:210K                                   Toppan Merrill/FA
 6/13/23  Accelerate Diagnostics, Inc.      8-K:1,2,3,7 6/09/23   18:7.9M                                   Toppan Merrill/FA
 5/24/23  Accelerate Diagnostics, Inc.      8-K:3,5,9   5/18/23   12:239K                                   Toppan Merrill/FA
 5/15/23  Accelerate Diagnostics, Inc.      10-Q        3/31/23   94:9.1M                                   Workiva Inc Wde… FA01/FA
 4/24/23  Accelerate Diagnostics, Inc.      8-K:1,9     4/21/23   11:630K                                   Toppan Merrill/FA
 3/14/23  Accelerate Diagnostics, Inc.      8-K:1,9     3/09/23   11:314K                                   Toppan Merrill/FA
11/14/22  Accelerate Diagnostics, Inc.      10-Q        9/30/22   97:10M                                    Workiva Inc Wde… FA01/FA
 8/15/22  Accelerate Diagnostics, Inc.      8-K:1,2,3,9 8/15/22   15:741K                                   Toppan Merrill/FA
 5/17/22  Accelerate Diagnostics, Inc.      8-K:3,5,9   5/12/22   12:406K                                   Toppan Merrill/FA
 3/25/22  Accelerate Diagnostics, Inc.      8-K:1,3,9   3/24/22   11:302K                                   Toppan Merrill/FA
 2/03/22  Accelerate Diagnostics, Inc.      8-K:5,9     2/02/22   11:204K                                   Toppan Merrill/FA
 9/23/21  Accelerate Diagnostics, Inc.      8-K:1,3,5,9 9/17/21   15:612K                                   Toppan Merrill/FA
 5/13/21  Accelerate Diagnostics, Inc.      8-K:3,5,9   5/07/21   11:219K                                   Toppan Merrill/FA
12/28/20  Accelerate Diagnostics, Inc.      8-K:1,3,7,912/24/20   12:439K                                   Toppan Merrill/FA
 5/14/20  Accelerate Diagnostics, Inc.      8-K:5,9     5/08/20   11:215K                                   Toppan Merrill/FA
 2/28/20  Accelerate Diagnostics, Inc.      10-K       12/31/19  103:10M                                    Workiva Inc Wde… FA01/FA
 8/08/19  Accelerate Diagnostics, Inc.      8-K:2,5,8,9 8/02/19    6:459K                                   Toppan Merrill/FA
 5/15/19  Accelerate Diagnostics, Inc.      8-K:5,9     5/10/19    3:58K                                    Toppan Merrill/FA
 3/01/19  Accelerate Diagnostics, Inc.      10-K       12/31/18   99:9.1M                                   Workiva Inc Wde… FA01/FA
11/06/18  Accelerate Diagnostics, Inc.      10-Q        9/30/18   76:5.6M                                   Workiva Inc Wde… FA01/FA
 3/28/18  Accelerate Diagnostics, Inc.      8-K:1,2,3,8 3/22/18    6:1M                                     Toppan Merrill/FA
 4/10/17  Accelerate Diagnostics, Inc.      DEF 14A     5/04/17    1:792K                                   Toppan Merrill/FA
 3/15/16  Accelerate Diagnostics, Inc.      8-K:8,9     3/10/16    2:28K                                    Toppan Merrill/FA
 7/12/13  Accelerate Diagnostics, Inc.      DEF 14C     7/12/13    1:106K                                   Toppan Merrill/FA
 3/22/13  Accelerate Diagnostics, Inc.      S-8         3/22/13    6:140K                                   Toppan Merrill/FA
11/13/12  Accelerate Diagnostics, Inc.      DEF 14A    12/12/12    1:1M                                     Mitchell Fi… Printing/FA
10/26/12  Accelerate Diagnostics, Inc.      10-K        7/31/12   84:8M                                     Mitchell Fi… Printing/FA
Top
Filing Submission 0001628280-24-013670   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 1:53:22.2am ET